New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07347951
First seen Jan 18, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests a new treatment plan for people with a certain type of locally advanced rectal cancer (MSS-type). The plan combines short-course radiation, chemotherapy, and two drugs (serplulimab and bevacizumab) before surgery. The goal is to see if this approach can eliminate all cancer cells by the time of surgery, potentially allowing more patients to avoid a permanent colostomy. About 30 adults aged 18-75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.